行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

1.550
-0.020
-1.27%
已收盘, 16:00 04/20 EDT
开盘
1.520
昨收
1.570
最高
1.590
最低
1.510
成交量
8.96万
成交额
--
52周最高
5.36
52周最低
0.6663
市值
4,427.93万
市盈率(TTM)
-3.2420
分时
5日
1月
3月
1年
5年
纳米药物市场的潜在增长，份额，需求，主要参与者的分析以及对2020-2027年的预测作者：Ameco Research
pune, India, Fri, 16 Apr 2021 05:05:21 / Comserve Inc. / -- A new research report titled "Nano-Drug Market" successfully exhibits the complete scenario of...
Comserve · 4天前
2021年前哨淋巴结活检市场规模Covid-19对行业份额，CAGR状态，趋势分析，顶级制造商，增长因素，推动因素以及至2027年全球预测的影响
Apr 16, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Sentinel Node Biopsy Market” report...
The Express Wire · 4天前
Navidea生物世界知识产权组织的专利范围清单。
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021067479&tab=PCTDESCRIPTION
Benzinga · 04/08 19:47
2020年前哨淋巴结活检市场规模：借助360个市场更新，对2026年研究报告的增长因素，定义，业务机会，趋势，细分和预测
Apr 08, 2021 (The Expresswire) -- “ Sentinel Node Biopsy Market “ size is expected to raise remarkably, most important trends, impact of COVID-19 , market...
The Express Wire · 04/08 06:49
BRIEF-Navidea Says Board Approved Adoption Of An Amendment To Company's Amended And Restated Bylaws
reuters.com · 04/05 20:23
10-K：NAVIDEA生物制药公司
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be...
Edgar Online - (EDG = 10Q, 10K) · 03/26 21:03
Navidea（NAVB）获得美信集团的买入评级
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Navidea (NAVB) yesterday and set a price target of $7.00. The company's shares
SmarterAnalyst · 03/26 11:35
分析师对医疗保健公司提供见解：Navidea（NAVB）和Monopar Therapeutics Inc（MNPR）
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Navidea (NAVB) and Monopar Therapeutics Inc (MNPR) with
SmarterAnalyst · 03/25 14:35
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解NAVB最新的财务预测，通过NAVB每股收益，每股净资产，每股现金流等数据分析Navidea生物制药近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测NAVB价格均价为7.50，最高价位8.00，最低价为7.00。
EPS
机构持股
总机构数: 32
机构持股: 74.28万
持股比例: 2.60%
总股本: 2,856.73万
类型机构数股数
增持
7
15.81万
建仓
5
3.67万
减持
8
2.59万
平仓
24
8.40万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.29%
制药与医学研究
+0.33%
高管信息
Chairman/Independent Director
Michael Rice
Chairman/Independent Director
Y. Michael Rice
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
Malcolm Witter
Independent Director
Claudine Bruck
Independent Director
Kathy Rouan
Independent Director
Adam Cutler
Independent Director
S. Kathryn Rouan
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
NAVB 简况
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NAVB股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NAVB股票基本功能。